[1]汪文霞,兰晓莉,张永学.HER2的表达及其分子影像的研究进展[J].国际放射医学核医学杂志,2016,40(5):363-373.[doi:10.3760/cma.j.issn.1673-4114.2016.05.007]
　Wang Wenxia,Lan Xiaoli,Zhang Yongxue.Research and development of HER2 expression molecular imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):363-373.[doi:10.3760/cma.j.issn.1673-4114.2016.05.007]
点击复制

HER2的表达及其分子影像的研究进展(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
40
期数:
2016年第5期
页码:
363-373
栏目:
综述
出版日期:
2016-09-25

文章信息/Info

Title:
Research and development of HER2 expression molecular imaging
作者:
汪文霞;  兰晓莉;  张永学
430022 武汉, 华中科技大学同济医学院附属协和医院核医学分子影像研究所, 湖北省分子影像重点实验室, 教育部分子靶向治疗重点实验室
Author(s):
Wang Wenxia;  Lan Xiaoli;  Zhang Yongxue
Hubei Province Key Laboratory of Molecular Imaging, Key Laboratory of Molecular Targeted Therapies of the Ministry of Education, Institute of Nuclear Medicine and Molecular Imaging, Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan 430022, China
关键词:
人表皮生长因子受体2; 分子探针; 抗体; 单克隆; 分子显像; 纳米抗体
Keywords:
Human epidermal growth factor receptor-2; Molecular probe; Antibodies; monoclonal; Molecular imaging; Nanobody
DOI:
10.3760/cma.j.issn.1673-4114.2016.05.007
摘要:
人表皮生长因子受体2（HER2）是一种具有酪氨酸激酶活性的跨膜受体，同时也是一种高表达于各种癌细胞的生物标志物。高表达HER2的肿瘤往往预后不良。HER2分子影像主要是利用放射性核素、磁性材料、发光物质等标记配体能与HER2特异性结合的特性，对患者体内HER2高表达病灶进行显像，从而协助HER2阳性疾病的诊断，筛选出抗HER2治疗有效的患者，并可用于疗效评估，是近年来肿瘤精准医疗研究的热点之一。
Abstract:
Human epidermal growth factor receptor-2(HER2) is a kind of transmembrane receptor with tyrosine kinase activity, and also is a biomarker highly expressed in various cancer cells, often indicating poor clinical prognosis. HER2 expression molecular imaging mainly utilizes the labeled-ligands’ ability of specific binding with HER2, such as radionuclide, magnetic materials and fluorescent substances, by which the high-HER2 expressed lesions are shown. This technique provides a strong support for diagnosing HER2-expressed diseases, selecting patients who are respondent to HER2-targeted therapy and evaluating the therapeutic effect, and has become one of the hot spots in the research of precise treatment of tumors in recent years.

参考文献/References:

[1] Schechter AL, Stern DF, Vaidyanathan L, et al.The neu oncogene:an erb-B-related gene encoding a 185, 000-Mr tumour antigen[J].Nature, 1984, 312(5994):513-516.
[2] Siegel R, Naishadham D, Jemal A.Cancer statistics, 2013[J].CA Cancer J Clin, 2013, 63(1):11-30.DOI:10.3322/caac.21166.
[3] 刘芳, 唐光才.乳腺癌影像诊断的研究现状[J].国际医学放射学杂志, 2013, 36(6):533-537.DOI:10.3874/j.issn.1674-1897.2013.06.Z0605.Liu F, Tang GC.The current status of imaging diagnosis of breast cancer[J].Int J Med Radiol, 2013, 36(6):533-537.
[4] King CR, Kraus MH, Aaronson SA.Amplification of a novel v-erbB-related gene in a human mammary carcinoma[J].Science, 1985, 229(4717):974-976.DOI:10.1126/science.2992089.
[5] Slamon DJ, Clark GM, Wong SG, et al.Human breast cancer:correlation of relapse and survival with amplification of the HER-2/neu oncogene[J].Science, 1987, 235(4785):177-182.DOI:10.1126/science.3798106.
[6] Ross JS, Slodkowska EA, Symmans WF, et al.The HER-2 receptor and breast cancer:ten years of targeted anti-HER-2 therapy and personalized medicine[J].Oncologist, 2009, 14(4):320-368.DOI:10.1634/theoncologist.2008-0230.
[7] Fu W, Lobocki CA, Silberberg BK, et al.Molecular markers in Paget disease of the breast[J].J Surg Oncol, 2001, 77(3):171-178.DOI:10.1002/jso.1090.
[8] Debska-Szmich S, Krakowska M, Czernek U, et al.The role of preoperative systemic treatment in patients with breast cancer[J].Contemp Oncol(Pozn), 2016, 20(2):93-101.DOI:10.5114/wo.2016.60067.
[9] Zhang B, Cai FF, Zhong XY.An overview of biomarkers for the ovarian cancer diagnosis[J].Eur J Obstet Gynecol Reprod Biol, 2011, 158(2):119-123.DOI:10.1016/j.ejogrb.2011.04.023.
[10] Corney DC, Hwang CI, Matoso A, et al.Frequent downregulation of miR-34 family in human ovarian cancers[J].Clin Cancer Res, 2010, 16(4):1119-1128.DOI:10.1158/1078-0432.CCR-09-2642.
[11] Verri E, Guglielmini P, Puntoni M, et al.HER2/neu oncoprotein overexpression in epithelial ovarian cancer:evaluation of its prevalence and prognostic significance.Clinical study[J].Oncology, 2005, 68(2/3):154-161.DOI:10.1159/000086958.
[12] Tanabe H, Nishii H, Sakata A, et al.Overexpression of HER-2/neu is not a risk factor in ovarian clear cell adenocarcinoma[J].Gynecol Oncol, 2004, 94(3):735-739.DOI:10.1016/j.ygyno.2004.05.055.
[13] Mano MS, Awada A, Di LA, et al.Rates of topoisomerase Ⅱ-alpha and HER-2 gene amplification and expression in epithelial ovarian carcinoma[J].Gynecol Oncol, 2004, 92(3):887-895.DOI:10.1016/j.ygyno.2003.12.010.
[14] Bookman MA, Darcy KM, Clarke-Pearson D, et al.Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2:a phase Ⅱ trial of the Gynecologic Oncology Group[J].J Clin Oncol, 2003, 21(2):283-290.DOI:10.1200/JCO.2003.10.104.
[15] Tuefferd M, Couturier J, Penault-Llorca F, et al.HER2 status in ovarian carcinomas:a multicenter GINECO study of 320 patients[J/OL].PLoS One, 2007, 2(11):1138[2016-08-03].http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0001138.DOI:10.1371/journal.pone.0001138.
[16] Suo Z, Karbovo E, Karbove K, et al.Papillary serous carcinoma of the ovary:an ultrastructural and immunohistochemical study[J].Ultrastruct Pathol, 2004, 28(3):141-147.DOI:10.1080/01913120490475716.
[17] O’Neill CJ, Deavers MT, Malpica A, et al.An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas:significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms[J].Am J Surg Pathol, 2005, 29(8):1034-1041.
[18] Wang D, Zhu H, Ye Q, et al.Prognostic Value of KIF2A and HER2-Neu Overexpression in Patients with Epithelial Ovarian Cancer[J/OL].Medicine(Baltimore), 2016, 95(8):2803[2016-08-03].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4779007/.DOI:10.1097/MD.0000000000002803.
[19] Chen WQ, Zheng RS, Zhang SW, et al.Annual report on status of cancer in China, 2010[J].Chin J Cancer Res, 2014, 26(1):48-58.DOI:10.3978/j.issn.1000-9604.2014.01.08.
[20] Abraháo-Machado LF, Jácome AA, Wohnrath DR, et al.HER2 in gastric cancer:comparative analysis of three different antibodies using whole-tissue sections and tissue microarrays[J].World J Gastroenterol, 2013, 19(38):6438-6446.DOI:10.3748/wjg.v19.i38.6438.
[21] Bang YJ, Van Cutsem E, Feyereislova A, et al.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer(ToGA):a phase 3, open-label, randomised controlled trial[J].Lancet, 2010, 376(9742):687-697.DOI:10.1016/S0140-6736(10)61121-X.
[22] Liang JW, Zhang JJ, Zhang T, et al.Clinicopathological and prognostic significance of HER2 overexpression in gastric cancer:a meta-analysis of the literature[J].Tumour Biol, 2014, 35(5):4849-4858.DOI:10.1007/s13277-014-1636-3.
[23] Moelans CB, Milne AN, Morsink FH, et al.Low frequency of HER2 amplification and overexpression in early onset gastric cancer[J].Cell Oncol(Dordr), 2011, 34(2):89-95.DOI:10.1007/s13402-011-0021-0.
[24] Chen C, Yang JM, Hu TT, et al.Prognostic role of human epidermal growth factor receptor in gastric cancer:a systematic review and meta-analysis[J].Arch Med Res, 2013, 44(5):380-389.DOI:10.1016/j.arcmed.2013.07.001.
[25] Fisher SB, Fisher KE, Squires MH 3rd, et al.HER2 in resected gastric cancer:Is there prognostic value?[J].J Surg Oncol, 2014, 109(2):61-66.DOI:10.1002/jso.23456.
[26] Shen GS, Zhao JD, Zhao JH, et al.Association of HER2 status with prognosis in gastric cancer patients undergoing R0 resection:A large-scale multicenter study in China[J].World J Gastroenterol, 2016, 22(23):5406-5414.DOI:10.3748/wjg.v22.i23.5406.
[27] 任新瑜, 尹玉峰, 高洁, 等.中国人群胰腺癌与胃癌HER2/neu基因表达[J].协和医学杂志, 2012, 3(1):21-25.DOI:10.3969/j.issn.1674-9081.2012.01.006.Ren XY, Yin YF, Gao J, et al.Detection of HER2/neu Gene in Pancreatic and Gastric Adenocarcinoma among Chinese Patients[J].Med J Peking Union Med Coll Hosp, 2012, 3(1):21-25.
[28] Aumayr K, Soleiman A, Sahora K, et al.HER2 gene amplification and protein expression in pancreatic ductal adenocarcinomas[J].Appl Immunohistochem Mol Morphol, 2014, 22(2):146-152.DOI:10.1097/PAI.0b013e31828dc392.
[29] Ata A, Polat A, Serins?z E, et al.Prognostic value of increased HER2 expression in cancers of pancreas and biliary tree[J].Pathol Oncol Res, 2015, 21(3):831-838.DOI:10.1007/s12253-014-9847-x.
[30] Liu HL, Gandour-Edwards R, Lara PN, et al.Detection of low level HER-2/neu gene amplification in prostate cancer by fluorescence in situ hybridization[J].Cancer J, 2001, 7(5):395-403.
[31] Ross JS, Sheehan CE, Hayner-Buchan AM, et al.Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma[J].Cancer, 1997, 79(11):2162-2170.DOI:10.1002/(SICI)1097-0142(19970601)79:11<2162:AID-CNCR14>3.0.CO;2-U.
[32] Signoretti S, Montironi R, Manola J, et al.Her-2-neu expression and progression toward androgen independence in human prostate cancer[J].J Natl Cancer Inst, 2000, 92(23):1918-1925.DOI:10.1093/jnci/92.23.1918.
[33] Andersson J, Rosestedt M, Orlova A.Imaging of HER2 may improve the outcome of external irradiation therapy for prostate cancer patients[J].Oncol Lett, 2015, 9(2):950-954.DOI:10.3892/ol.2014.2760.
[34] 邓在春, 俞文英, 胡国平, 等.erbB1/HER1和erbB2/HER2在肺癌的表达[J].现代实用医学, 2001, 13(11):539-541.DOI:10.3969/j.issn.1671-0800.2001.11.003.Deng ZC, Yu WY, Hu GP, et al.Expression of erbB1/HER1 and erbB2/HER2 in hung cancer[J].Modern Pract Med, 2001, 13(11):539-541.
[35] Shen H, Du G, Liu Z, et al.Assessment and prognostic analysis of EGFR mutations or/and HER2 overexpression in Uygur’s Non-small Cell Lung Cancer[J].Int J Clin Exp Med, 2015, 8(12):22300-22309.
[36] Han Y, Xu JM, Duan HQ, et al.Correlation of epidermal growth factor receptor mutations and HER2/3 protein expression with clinical outcome in advanced non-small cell lung cancer patients treated with gefitinib[J].Chin J Cancer, 2010, 29(1):69-75.
[37] Dijkers EC, Kosterink JG, Rademaker AP, et al.Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging[J].J Nucl Med, 2009, 50(6):974-981.DOI:10.2967/jnumed.108.060392.
[38] Oude Munnink TH, Korte MA, Nagengast WB, et al.89Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft[J].Eur J Cancer, 2010, 46(3):678-684.DOI:10.1016/j.ejca.2009.12.009.
[39] Lub-de Hooge MN, Kosterink JG, Perik PJ, et al.Preclinical characterisation of 111In-DTPA-trastuzumab[J].Br J Pharmacol, 2004, 143(1):99-106.DOI:10.1038/sj.bjp.0705915.
[40] N Tinianow J, Pandya DN, Pailloux SL, et al.Evaluation of a 3-hydroxypyridin-2-one(2, 3-HOPO) Based Macrocyclic Chelator for 89Zr(4+) and Its Use for ImmunoPET Imaging of HER2 Positive Model of Ovarian Carcinoma in Mice[J].Theranostics, 2016, 6(4):511-521.DOI:10.7150/thno.14261.
[41] Smith-Jones PM, Solit DB, Akhurst T, et al.Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors[J].Nat Biotechnol, 2004, 22(6):701-706.DOI:10.1038/nbt968.
[42] Smith-Jones PM, Solit D, Afroze F, et al.Early tumor response to Hsp90 therapy using HER2 PET:comparison with 18F-FDG PET[J].J Nucl Med, 2006, 47(5):793-796.
[43] Dennis MS, Jin H, Dugger D, et al.Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent[J].Cancer Res, 2007, 67(1):54-261.DOI:10.1158/0008-5472.CAN-06-2531.
[44] Orlova A, Tolmachev V, Pehrson R, et al.Synthetic affibody molecules:a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors[J].Cancer Res, 2007, 67(5):2178-2186.DOI:10.1158/0008-5472.CAN-06-2887.
[45] Kramer-Marek G, Kiesewetter DO, Capala J.Changes in HER2 expression in breast cancer xenografts after therapy can be quantified using PET and 18F-labeled affibody molecules[J].J Nucl Med, 2009, 50(7):1131-1139.DOI:10.2967/jnumed.108.057695.
[46] Ahlgren S, W?llberg H, Tran TA, et al.Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine[J].J Nucl Med, 2009, 50(5):781-789.DOI:10.2967/jnumed.108.056929.
[47] Orlova A, W?llberg H, Stone-Elander S, et al.On the selection of a tracer for PET imaging of HER2-expressing tumors:direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model[J].J Nucl Med, 2009, 50(3):417-425.DOI:10.2967/jnumed.108.057919.
[48] S?rensen J, Sandberg D, Sandstr?m M, et al.First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule[J].J Nucl Med, 2014, 55(5):730-735.DOI:10.2967/jnumed.113.131243.
[49] S?rensen J, Velikyan I, Sandberg D, et al.Measuring HER2-receptor Expression In Metastatic Breast Cancer Using[68Ga]ABY-025 Affibody PET/CT[J].Theranostics, 2016, 6(2):262-271.DOI:10.7150/thno.13502.
[50] Westerlund K, Honarvar H, Norrstr?m E, et al.Increasing the Net Negative Charge by Replacement of DOTA Chelator with DOTAGA Improves the Biodistribution of Radiolabeled Second-Generation Synthetic Affibody Molecules[J].Mol Pharm, 2016, 13(5):1668-1678.DOI:10.1021/acs.molpharmaceut.6b00089.
[51] 蔡炯, 党永红, 郑堃, 等.含末端半胱氨酸人表皮生长因子受体2亲和体的68Ga标记和显像[J].中华核医学与分子影像杂志, 2013, 33(6):460-463.DOI:10.3760/cma.j.issn.2095-2848.2013.06.014.Cai J, Dang YH, Zheng K, et al.68Ga-labeled HER2 affibody with C-terminal cysteine and its PET imaging[J].Chin J Nucl Med Mol Imaging, 2013, 33(6):460-463.
[52] Honarvar H, Westerlund K, Altai M, et al.Feasibility of Affibody Molecule-Based PNA-Mediated Radionuclide Pretargeting of Malignant Tumors[J].Theranostics, 2016, 6(1):93-103.DOI:10.7150/thno.12766.
[53] Strand J, Nordeman P, Honarvar H, et al.Site-Specific Radioiodination of HER2-Targeting Affibody Molecules using 4-Iodophenethyl-maleimide Decreases Renal Uptake of radioactivity[J].Chemistry-Open, 2015, 4(2):174-182.DOI:10.1002/open.201402097.
[54] Miller J, Doss M, McQuillen R, et al.Impact of expression system on the function of the C6.5 diabody PET radiotracer[J].Tumour Biol, 2012, 33(3):617-627.DOI:10.1007/s13277-012-0361-z.
[55] Robinson MK, Doss M, Shaller C, et al.Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody[J].Cancer Res, 2005, 65(4):1471-1478.DOI:10.1158/0008-5472.CAN-04-2008.
[56] Reddy S, Shaller CC, Doss M, et al.Evaluation of the anti-HER2 C6.5 diabody as a PET radiotracer to monitor HER2 status and predict response to trastuzumab treatment[J].Clin Cancer Res, 2011, 17(6):1509-1520.DOI:10.1158/1078-0432.CCR-10-1654.
[57] Sedgwick SG, Smerdon SJ.The ankyrin repeat:a diversity of interactions on a common structural framework[J].Trends Biochem Sci, 1999, 24(8):311-316.
[58] Zahnd C, Kawe M, Stumpp MT, et al.Efficient tumor targeting with high-affinity designed ankyrin repeat proteins:effects of affinity and molecular size[J].Cancer Res, 2010, 70(4):1595-1605.DOI:10.1158/0008-5472.CAN-09-2724.
[59] Goldstein R, Sosabowski J, Livanos M, et al.Development of the designed ankyrin repeat protein(DARPin) G3 for HER2 molecular imaging[J].Eur J Nucl Med Mol Imaging, 2015, 42(2):288-301.DOI:10.1007/s00259-014-2940-2.
[60] Mironova KE, Chernykh ON, Ryabova AV, et al.Highly specific hybrid protein DARPin-mCherry for fluorescent visualization of cells overexpressing tumor marker HER2/neu[J].Biochemistry(Mosc), 2014, 79(12):1391-1396.DOI:10.1134/S0006297914120141.
[61] Hamers-Casterman C, Atarhouch T, Muyldermans S, et al.Naturally occurring antibodies devoid of light chains[J].Nature, 1993, 363(6428):446-448.DOI:10.1038/363446a0.
[62] Vaneycken I, Devoogdt N, Van Gassen N, et al.Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer[J].FASEB J, 2011, 25(7):2433-2446.DOI:10.1096/fj.10-180331.
[63] D’Huyvetter M, Aerts A, Xavier C, et al.Development of 177Lu-nanobodies for radioimmunotherapy of HER2-positive breast cancer:evaluation of different bifunctional chelators[J].Contrast Media Mol Imaging, 2012, 7(2):254-264.DOI:10.1002/cmmi.491.
[64] Xavier C, Blykers A, Vaneycken I, et al.18F-nanobody for PET imaging of HER2 overexpressing tumors[J].Nucl Med Biol, 2016, 43(4):247-252.DOI:10.1016/j.nucmedbio.2016.01.002.
[65] Vaidyanathan G, McDougald D, Choi J, et al.Preclinical evaluation of 18F-labeled anti-HER2 nanobody conjugates for imaging HER2 receptor expression by immuno-PET[J].J Nucl Med, 2016, 57(6):967-973.DOI:10.2967/jnumed.115.171306.
[66] Massa S, Vikani N, Betti C, et al.Sortase A-mediated site-specific labeling of camelid single-domain antibody-fragments:a versatile strategy for multiple molecular imaging modalities[J/OL].Contrast Media Mol Imaging, 2016[2016-08-03].http://onlinelibrary.wiley.com/doi/10.1002/cmmi.1696/pdf.DOI:10.1002/cmmi.1696.
[67] 朱媛, 段小艺, 王瑞峰, 等.乳腺癌HER2靶向分子探针的制备及体外MRI初步研究[J].中国医学影像学杂志, 2014, 22(5):336-339.DOI:10.3969/j.issn.1005-5185.2014.05.005.Zhu Y, Duan XY, Wang RF, et al.Preparation of HER2-targeted molecular probe and its MR imaging in Vitro[J].Chin J Med Imaging, 2014, 22(5):336-339.
[68] Ding N, Sano K, Kanazaki K, et al.In Vivo HER2-Targeted Magnetic resonance tumor Imaging Using Iron Oxide Nanoparticles Conjugated with Anti-HER2 Fragment Antibody[J/OL].Mol Imaging Biol, 2016[2016-08-03].http://link.springer.com/article/10.1007/s11307-016-0977-2.DOI:10.1007/s11307-016-0977-2.
[69] Yang H, Cai W, Xu L, et al.Nanobubble-Affibody:Novel ultrasound contrast agents for targeted molecular ultrasound imaging of tumor[J].Biomaterials, 2015, 37:279-288.DOI:10.1016/j.biomaterials.2014.10.013.
[70] Dong X, Gu Y.Application of optical molecular imaging technology in the diagnosis and treatment of diseases[J].J Chin Pharm Univ, 2014, 45(2):145-152.DOI:10.11665/j.issn.1000-5048.20140203
[71] Ag D, Bongartz R, Dogan LE, et al.Biofunctional quantum dots as fluorescence probe for cell-specific targeting[J].Colloids Surf B Biointerfaces, 2014, 114:96-103.DOI:10.1016/j.colsurfb.2013.09.033.
[72] Rakovich TY, Mahfoud OK, Mohamed BM, et al.Highly sensitive single domain antibody-quantum dot conjugates for detection of HER2 biomarker in lung and breast cancer cells[J].ACS Nano, 2014, 8(6):5682-5695.DOI:10.1021/nn500212h.
[73] Tu CC, Chen KP, Yang TA, et al.Silicon quantum dot nanoparticles with antifouling coatings for immunostaining on live cancer cells[J].ACS Appl Mater Interfaces, 2016, 8(22):13714-13723.DOI:10.1021/acsami.6b02318.
[74] Michalska M, Florczak A, Dams-Kozlowska H, et al.Peptide-functionalized ZCIS QDs as fluorescent nanoprobe for targeted HER2-positive breast cancer cells imaging[J].Acta Biomater, 2016, 35:293-304.DOI:10.1016/j.actbio.2016.02.002.
[75] Zhao N, Liu S, Jiang Q, et al.Small-protein-stabilized semiconductor nanoprobe for targeted imaging of cancer cells[J].Chembiochem, 2016, 17(13):1202-1206.DOI:10.1002/cbic.201600219.

相似文献/References:

[1]张晓,兰晓莉,胡帆,等.点击化学在分子影像学中的应用和进展[J].国际放射医学核医学杂志,2016,40(3):196.[doi:10.3760/cma.j.issn.1673-4114.2016.03.008]
　Zhang Xiao,Lan Xiaoli,Hu Fan,et al.Applications and advances of click chemistry in molecular imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):196.[doi:10.3760/cma.j.issn.1673-4114.2016.03.008]
[2]解朋,黄建敏,张芳,等.99Tcm-MAG3-isoDGR-2C分子探针的制备与体内分布的实验研究[J].国际放射医学核医学杂志,2016,40(5):345.[doi:10.3760/cma.j.issn.1673-4114.2016.05.004]
　Xie Peng,Huang Jianmin,Zhang Fang,et al.Labeling MAG3-isoDGR-2C with 99Tcm and its biodistribution in mice[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):345.[doi:10.3760/cma.j.issn.1673-4114.2016.05.004]
[3]安淑娴,宋少莉,黄钢.放射性核素标记的凋亡显像剂的研究进展[J].国际放射医学核医学杂志,2015,39(6):470.[doi:10.3760/cma.j.issn.1673-4114.2015.06.008]
　An Shuxian,Song Shaoli,Huang Gang.Recent advances in apoptosis imaging using radionuclide-labeled tracers[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):470.[doi:10.3760/cma.j.issn.1673-4114.2015.06.008]
[4]李帅,李剑明.动脉粥样硬化易损斑块放射性核素标记分子探针的研究进展[J].国际放射医学核医学杂志,2015,39(1):80.[doi:10.3760/cma.j.issn.1673-4114.2015.01.017]
　Li Shuai,Li Jianming.Research progress of molecular probes labeled with radionuclide for imaging of atherosclerosis vulnerable plaque[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):80.[doi:10.3760/cma.j.issn.1673-4114.2015.01.017]
[5]林潇,唐明灯.靶向表皮生长因子受体分子探针研究进展[J].国际放射医学核医学杂志,2015,39(1):85.[doi:10.3760/cma.j.issn.1673-4114.2015.01.018]
　Lin Xiao,Tang Mingdeng.Research progresses on molecular probes targeting epidermal growth factor receptor[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):85.[doi:10.3760/cma.j.issn.1673-4114.2015.01.018]
[6]孔艳艳,管一晖,吴平.PET分子探针在阿尔茨海默病早期诊断中的研究进展[J].国际放射医学核医学杂志,2012,36(5):257.[doi:10.3760/cnla.j.issn.1673-4114.2012.05.001]
　KONG Yan-yan,GUAN Yi-hui,WU Ping.Novel PET molecular probes for early diagnosis of Alzheimer’s disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(5):257.[doi:10.3760/cnla.j.issn.1673-4114.2012.05.001]
[7]吴涛,安锐.分子影像报告基因系统的研究进展[J].国际放射医学核医学杂志,2010,34(4):198.[doi:10.3760/cma.j.issn.1673-4114.2010.04.002]
　WU Tao,AN Rui.Advances in study of molecular imaging reporter gene systems[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(5):198.[doi:10.3760/cma.j.issn.1673-4114.2010.04.002]
[8]陈铨,张永学.分子成像技术的研究进展[J].国际放射医学核医学杂志,2011,35(5):290.[doi:10.3760/cma.j.issn.1673-4114.2011.05.010]
　CHEN Quan,ZHANG Yong-xue.Progress on molecular imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(5):290.[doi:10.3760/cma.j.issn.1673-4114.2011.05.010]
[9]曹丰,陈跃.双模式分子影像探针研究进展[J].国际放射医学核医学杂志,2010,34(1):1.[doi:10.3760/cma.j.issn.1673-4114.2010.01.001]
　CAO Feng,CHEN Yue.The research progress of dual-modality probes for molecular imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(5):1.[doi:10.3760/cma.j.issn.1673-4114.2010.01.001]
[10]蔡汉成,尹端沚,张岚,等.早期诊断阿尔茨海默病的PET分子探针[J].国际放射医学核医学杂志,2006,30(4):202.
　CAI Han-cheng,YIN Duan-zhi,ZHANG Lan,et al.PET molecular probes for early detection of Alzheimer’s disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(5):202.

备注/Memo

备注/Memo:
收稿日期:2016-08-04
基金项目:国家自然科学基金重点项目(31630049)
通讯作者:张永学,Email:zhyx1229@163.com
更新日期/Last Update: 1900-01-01